This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Purnell, D. M. Articles by Biro, T. G. Search for Related Content PubMed PubMed Citation Articles by Purnell, D. M. Articles by Biro, T. G.

Corynebacterium parvum and Cyclophosphamide as Combination Treatment for a Murine Mammary Adenocarcinoma¹

Departments of Pathology [D.M.P., G.L.B., J.W.K., T.G.B.] and Microbiology [G.L.B., J.W.K.] and Specialized Cancer Research Center [D.M.P., G.L.B., J.W.K.], College of Medicine, The Pennsylvania State University, Hershey, Pennsylvania 17033

Weekly i.p. injections of killed Corynebacterium parvum and of cyclophosphamide (given on different days) strongly inhibited growth of a transplantable murine mammary adenocarcinoma. A significant portion (40 to 80%) of animals could be made tumor free by means of combined therapy. No tumor-free survivors were obtained with C. parvum alone, and tumor-free mice were obtained with cyclophosphamide alone only at the expense of a high incidence of deaths due to drug toxicity. No evidence of tumor rejection immunity was detected in the tumor-free survivors from the combined treatment protocols, suggesting that this therapeutic regimen is not associated with tumor rejection immunity.

¹ Supported by Contract NO1-CB-33891 and Grant P30-CA-18450 awarded by the National Cancer Institute, Department of Health, Education and Welfare, and by funds from the Jake Gittlen Memorial Golf Tournament.

² Recipient of USPHS Career Development Award KO4-CA-70948 from the National Cancer Institute.

Received 10/19/76. Accepted 1/11/77.